Development of Protein- and Peptide-Based HIV Entry Inhibitors Targeting Gp120 or Gp41

Overview

Journal Viruses

Publisher MDPI

Specialty Microbiology

Date 2019 Aug 4

PMID 31374953

Citations 19

Authors

Jing Pu

Qian Wang

Wei Xu

Lu Lu

Shibo Jiang

Affiliations

Soon will be listed here.

Abstract

Application of highly active antiretroviral drugs (ARDs) effectively reduces morbidity and mortality in HIV-infected individuals. However, the emergence of multiple drug-resistant strains has led to the increased failure of ARDs, thus calling for the development of anti-HIV drugs with targets or mechanisms of action different from those of the current ARDs. The first peptide-based HIV entry inhibitor, enfuvirtide, was approved by the U.S. FDA in 2003 for treatment of HIV/AIDS patients who have failed to respond to the current ARDs, which has stimulated the development of several series of protein- and peptide-based HIV entry inhibitors in preclinical and clinical studies. In this review, we highlighted the properties and mechanisms of action for those promising protein- and peptide-based HIV entry inhibitors targeting the HIV-1 gp120 or gp41 and discussed their advantages and disadvantages, compared with the current ARDs.

Citing Articles

The Role of Peptides in Combatting HIV Infection: Applications and Insights.

Helmy N, Parang K Molecules. 2024; 29(20).

PMID: 39459319 PMC: 11510642. DOI: 10.3390/molecules29204951.

gp120-derived amyloidogenic peptides form amyloid fibrils that increase HIV-1 infectivity.

Tan S, Li W, Yang C, Zhan Q, Lu K, Liu J Cell Mol Immunol. 2024; 21(5):479-494.

PMID: 38443447 PMC: 11061181. DOI: 10.1038/s41423-024-01144-y.

Strategic Approaches to Improvise Peptide Drugs as Next Generation Therapeutics.

Barman P, Joshi S, Sharma S, Preet S, Sharma S, Saini A Int J Pept Res Ther. 2023; 29(4):61.

PMID: 37251528 PMC: 10206374. DOI: 10.1007/s10989-023-10524-3.

The Effect of Treatment-Associated Mutations on HIV Replication and Transmission Cycles.

Johnson M, Jones C, Clark D Viruses. 2023; 15(1).

PMID: 36680147 PMC: 9861436. DOI: 10.3390/v15010107.

Design of human immunodeficiency virus-1 neutralizing peptides targeting CD4-binding site: An integrative computational biologics approach.

Vivekanandan S, Vetrivel U, Hanna L Front Med (Lausanne). 2022; 9:1036874.

PMID: 36465923 PMC: 9715589. DOI: 10.3389/fmed.2022.1036874.

References

Su S, Gong W, Gao J, Shen W, Grimm M, Deng X . T20/DP178, an ectodomain peptide of human immunodeficiency virus type 1 gp41, is an activator of human phagocyte N-formyl peptide receptor. Blood. 1999; 93(11):3885-92. View

Ferrer M, Harrison S . Peptide ligands to human immunodeficiency virus type 1 gp120 identified from phage display libraries. J Virol. 1999; 73(7):5795-802. PMC: 112640. DOI: 10.1128/JVI.73.7.5795-5802.1999. View

Vita C, Drakopoulou E, Vizzavona J, Rochette S, Martin L, Menez A . Rational engineering of a miniprotein that reproduces the core of the CD4 site interacting with HIV-1 envelope glycoprotein. Proc Natl Acad Sci U S A. 1999; 96(23):13091-6. PMC: 23905. DOI: 10.1073/pnas.96.23.13091. View

Gorny M, Zolla-Pazner S . Recognition by human monoclonal antibodies of free and complexed peptides representing the prefusogenic and fusogenic forms of human immunodeficiency virus type 1 gp41. J Virol. 2000; 74(13):6186-92. PMC: 112119. DOI: 10.1128/jvi.74.13.6186-6192.2000. View

Jacobson J, Lowy I, Fletcher C, ONeill T, Tran D, Ketas T . Single-dose safety, pharmacology, and antiviral activity of the human immunodeficiency virus (HIV) type 1 entry inhibitor PRO 542 in HIV-infected adults. J Infect Dis. 2000; 182(1):326-9. DOI: 10.1086/315698. View

Farzan M, Vasilieva N, Schnitzler C, Chung S, Robinson J, Gerard N . A tyrosine-sulfated peptide based on the N terminus of CCR5 interacts with a CD4-enhanced epitope of the HIV-1 gp120 envelope glycoprotein and inhibits HIV-1 entry. J Biol Chem. 2000; 275(43):33516-21. DOI: 10.1074/jbc.M007228200. View

Chen C, Greenberg M, Bolognesi D, Matthews T . Monoclonal antibodies that bind to the core of fusion-active glycoprotein 41. AIDS Res Hum Retroviruses. 2001; 16(18):2037-41. DOI: 10.1089/088922200750054765. View

Sanhadji K, Grave L, Touraine J, Leissner P, Rouzioux C, Firouzi R . Gene transfer of anti-gp41 antibody and CD4 immunoadhesin strongly reduces the HIV-1 load in humanized severe combined immunodeficient mice. AIDS. 2001; 14(18):2813-22. DOI: 10.1097/00002030-200012220-00002. View

Root M, Kay M, Kim P . Protein design of an HIV-1 entry inhibitor. Science. 2001; 291(5505):884-8. DOI: 10.1126/science.1057453. View

10.

Choi Y, Rho W, Kim N, Park S, Shin D, Kim J . Short peptides with induced beta-turn inhibit the interaction between HIV-1 gp120 and CD4. J Med Chem. 2001; 44(9):1356-63. DOI: 10.1021/jm000403+. View

11.

Louis J, Bewley C, Clore G . Design and properties of N(CCG)-gp41, a chimeric gp41 molecule with nanomolar HIV fusion inhibitory activity. J Biol Chem. 2001; 276(31):29485-9. DOI: 10.1074/jbc.C100317200. View

12.

Tillmann H, Heiken H, Heringlake S, Ockenga J, Wilber J, Goergen B . Infection with GB virus C and reduced mortality among HIV-infected patients. N Engl J Med. 2001; 345(10):715-24. DOI: 10.1056/NEJMoa010398. View

13.

Eckert D, Kim P . Design of potent inhibitors of HIV-1 entry from the gp41 N-peptide region. Proc Natl Acad Sci U S A. 2001; 98(20):11187-92. PMC: 58705. DOI: 10.1073/pnas.201392898. View

14.

Bewley C, Louis J, Ghirlando R, Clore G . Design of a novel peptide inhibitor of HIV fusion that disrupts the internal trimeric coiled-coil of gp41. J Biol Chem. 2002; 277(16):14238-45. DOI: 10.1074/jbc.M201453200. View

15.

Golding H, Zaitseva M, de Rosny E, King L, Manischewitz J, Sidorov I . Dissection of human immunodeficiency virus type 1 entry with neutralizing antibodies to gp41 fusion intermediates. J Virol. 2002; 76(13):6780-90. PMC: 136262. DOI: 10.1128/jvi.76.13.6780-6790.2002. View

16.

Michael Kilby J, Lalezari J, Eron J, Carlson M, Cohen C, Arduino R . The safety, plasma pharmacokinetics, and antiviral activity of subcutaneous enfuvirtide (T-20), a peptide inhibitor of gp41-mediated virus fusion, in HIV-infected adults. AIDS Res Hum Retroviruses. 2002; 18(10):685-93. DOI: 10.1089/088922202760072294. View

17.

Otaka A, Nakamura M, Nameki D, Kodama E, Uchiyama S, Nakamura S . Remodeling of gp41-C34 peptide leads to highly effective inhibitors of the fusion of HIV-1 with target cells. Angew Chem Int Ed Engl. 2002; 41(16):2937-40. DOI: 10.1002/1521-3773(20020816)41:16<2937::AID-ANIE2937>3.0.CO;2-J. View

18.

Martin L, Stricher F, Misse D, Sironi F, Pugniere M, Barthe P . Rational design of a CD4 mimic that inhibits HIV-1 entry and exposes cryptic neutralization epitopes. Nat Biotechnol. 2002; 21(1):71-6. DOI: 10.1038/nbt768. View

19.

Lalezari J, Henry K, OHearn M, Montaner J, Piliero P, Trottier B . Enfuvirtide, an HIV-1 fusion inhibitor, for drug-resistant HIV infection in North and South America. N Engl J Med. 2003; 348(22):2175-85. DOI: 10.1056/NEJMoa035026. View

20.

Lazzarin A, Clotet B, Cooper D, Reynes J, Arasteh K, Nelson M . Efficacy of enfuvirtide in patients infected with drug-resistant HIV-1 in Europe and Australia. N Engl J Med. 2003; 348(22):2186-95. DOI: 10.1056/NEJMoa035211. View